FI903845A0 - Renininhibitorer, foerfarande foer deras framstaellning och deras anvaendning i laekemedel. - Google Patents

Renininhibitorer, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.

Info

Publication number
FI903845A0
FI903845A0 FI903845A FI903845A FI903845A0 FI 903845 A0 FI903845 A0 FI 903845A0 FI 903845 A FI903845 A FI 903845A FI 903845 A FI903845 A FI 903845A FI 903845 A0 FI903845 A0 FI 903845A0
Authority
FI
Finland
Prior art keywords
deras
renininhibitorer
laekemedel
anvaendning
foerfarande foer
Prior art date
Application number
FI903845A
Other languages
English (en)
Finnish (fi)
Inventor
Wolfgang Bender
Guenther Kinast
Andreas Knorr
Johannes-Peter Stasch
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of FI903845A0 publication Critical patent/FI903845A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI903845A 1989-08-05 1990-08-02 Renininhibitorer, foerfarande foer deras framstaellning och deras anvaendning i laekemedel. FI903845A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3926021 1989-08-05
DE4004820A DE4004820A1 (de) 1989-08-05 1990-02-16 Renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln

Publications (1)

Publication Number Publication Date
FI903845A0 true FI903845A0 (fi) 1990-08-02

Family

ID=25883767

Family Applications (1)

Application Number Title Priority Date Filing Date
FI903845A FI903845A0 (fi) 1989-08-05 1990-08-02 Renininhibitorer, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.

Country Status (12)

Country Link
US (1) US5095006A (ja)
EP (1) EP0412350A3 (ja)
JP (1) JPH0381256A (ja)
KR (1) KR910004657A (ja)
AU (1) AU6019390A (ja)
CA (1) CA2022692A1 (ja)
DE (1) DE4004820A1 (ja)
FI (1) FI903845A0 (ja)
HU (1) HUT54386A (ja)
IE (1) IE902815A1 (ja)
IL (1) IL95265A0 (ja)
PT (1) PT94913A (ja)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE107658T1 (de) * 1988-01-26 1994-07-15 Sankyo Co Renin inhibierende polypeptide, ihre herstellung und anwendung.
JPH07501786A (ja) * 1991-07-02 1995-02-23 サンド・リミテッド ４−アミノ−３−ヒドロキシカルボン酸誘導体
TW217410B (ja) * 1992-04-01 1993-12-11 Ciba Geigy
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
DE4215874A1 (de) * 1992-05-14 1993-11-18 Bayer Ag Dithiolanylglycinhaltige HIV-Proteaseinhibitoren vom Hydroxyethylenisostertyp
CA2382547A1 (en) * 1999-09-21 2001-03-29 Stephen R. Hanson Methods and compositions for treating platelet-related disosders
ES2375268T3 (es) 2000-12-14 2012-02-28 The Brigham And Women's Hospital, Inc. Marcadores inflamatorios para la detección y prevención de diabetes mellitus.
US7297553B2 (en) * 2002-05-28 2007-11-20 Nanosphere, Inc. Method for attachment of silylated molecules to glass surfaces
HUE039881T2 (hu) 2002-05-09 2019-02-28 Brigham & Womens Hospital Inc 1L1RL-1, mint egy kardiovaszkuláris betegség-marker
US7273616B2 (en) * 2002-05-10 2007-09-25 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating Varicella zoster virus and methods of use thereof
AU2004266705A1 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
CA2536975A1 (en) * 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
EP1663184A2 (en) 2003-08-29 2006-06-07 The Brigham And Women's Hospital, Inc. Hydantoin derivatives as inhibitors of cellular necrosis
EP1697746B1 (en) 2003-12-05 2012-02-22 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
WO2005070006A2 (en) * 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
JP2007528402A (ja) * 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
WO2005087751A2 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
EP1734942A1 (en) * 2004-03-09 2006-12-27 Elan Pharmaceuticals, Inc. Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
CA2573138A1 (en) * 2004-07-09 2006-01-26 Elan Pharmaceuticals Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
WO2006010094A1 (en) * 2004-07-09 2006-01-26 Elan Pharmaceuticals, Inc. Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
WO2006026533A2 (en) * 2004-08-27 2006-03-09 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
EP1789388A2 (en) * 2004-08-27 2007-05-30 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using substituted ethanolcyclicamine aspartyl protease inhibitors
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
WO2006055542A2 (en) * 2004-11-15 2006-05-26 Nitromed, Inc. Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use
CA2595579A1 (en) * 2005-01-21 2006-07-27 Nitromed, Inc. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
SG175477A1 (en) * 2005-01-31 2011-11-28 Mylan Lab Inc Hydroxylated nebivolol metabolites
AU2006336387A1 (en) * 2005-02-16 2007-08-02 Nicox S.A. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
EP1858863A1 (en) * 2005-02-28 2007-11-28 Nitromed, Inc. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
EP1861093A2 (en) * 2005-03-09 2007-12-05 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
AP2896A (en) 2005-05-31 2014-05-31 Mylan Lab Inc Compositions comprising nebivolol
WO2007016677A2 (en) 2005-08-02 2007-02-08 Nitromed, Inc. Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
US20090054381A1 (en) * 2005-10-04 2009-02-26 Nitromed, Inc. Methods for treating respiratory disorders
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
CA2624904A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
WO2007047305A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US7838023B2 (en) * 2005-11-16 2010-11-23 Nitromed, Inc. Furoxan compounds, compositions and methods of use
EP1968584A2 (en) * 2005-12-20 2008-09-17 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
WO2007075542A2 (en) * 2005-12-22 2007-07-05 Nitromed, Inc. Nitric oxide enhancing pyruvate compounds, compositions and methods of use
US20080057590A1 (en) 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
AU2008242764B2 (en) 2007-04-18 2013-10-24 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
SG182821A1 (en) 2010-02-01 2012-08-30 Hospital For Sick Children Remote ischemic conditioning for treatment and prevention of restenosis
SG10201502031XA (en) 2010-03-31 2015-05-28 Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
US9265772B2 (en) 2012-05-11 2016-02-23 Reset Therapeutics, Inc. Carbazole-containing sulfonamides as cryptochrome modulators
EP2879666B1 (en) 2012-08-01 2020-04-08 Tavakoli, Zahra Free flowing, frozen compositions comprising a therapeutic agent
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1164239B (it) * 1983-05-25 1987-04-08 Anic Spa Un retro-inverso analogo del decapeptide (5-14)dell'angiotensinogeno equino inibitore specifico della renina con elevata resistenza all'idrolisi enzimatica
IT1164240B (it) * 1983-05-25 1987-04-08 Anic Spa Decapeptide parzialmente retro-invertito inibitore specifico della renina con elevata resistenza alla idrolisi enzimatica

Also Published As

Publication number Publication date
IL95265A0 (en) 1991-06-30
PT94913A (pt) 1991-04-18
CA2022692A1 (en) 1991-02-06
JPH0381256A (ja) 1991-04-05
IE902815A1 (en) 1991-02-27
EP0412350A3 (en) 1992-03-25
US5095006A (en) 1992-03-10
AU6019390A (en) 1991-02-07
EP0412350A2 (de) 1991-02-13
DE4004820A1 (de) 1991-04-25
KR910004657A (ko) 1991-03-29
HUT54386A (en) 1991-02-28

Similar Documents

Publication Publication Date Title
FI903845A0 (fi) Renininhibitorer, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
FI922037A0 (fi) Uppsvaellbart, brandhaerdigt och elledande bestrykningsmaterial.
FI895047A0 (fi) Tienopyridiner, deras framstaellning, mellanprodukter och farmaceutiska sammansaettningar innehaollande dessa foereningar.
FI915404A0 (fi) Endotermiska drivgaser, kompositioner och tillaempningar.
FI914144A0 (fi) Syrabestaendiga betongprodukter, speciellt svavelbetongroer och deras framstaellningfoerfarande.
FI901201A0 (fi) Antibakteriella 5-substituerade 1,4-dihydro-4-oxonaftyridin-3-karboxylatderivat och deras framstaellning.
FI891061A0 (fi) Kondenserade kinolinfoereningar, kondenserade akridinfoereningar, foerfarande foer framstaellning daerav och karsinostatiska kompositioner innehaollande desamma.
FI904823A0 (fi) Karboxylsyraestrar, naemnda karboxylsyraestrar innehaollande flytande kompositioner och foerfaranden foer smoerjning av metalldelar.
FI902686A0 (fi) Foerfarande foer framstaellning av dubbelsidigt belagda bandtransportoerer, i synnerhet foer pappers- och textilmaskiner, och anordning foer utfoering av foerfarandet.
FI905929A0 (fi) Anordning foer att oeverfoera skaerl, saosom flaskor, burkkar och dylika.
FI900682A0 (fi) Verktyg, paosaettningsmedel och ringanordning foer kedjor foer foerhindrande av glidning.
FI895286A0 (fi) Fenyloxipropanolaminer, deras framstaellning och terapeutiska anvaendning.
FI894677A (fi) Basiska 4-aryl-dhp-amider, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
FI901461A0 (fi) Underrede foer raelsfoerbundna godsvagn, saerskilt foer tankvagnar och kapslade bulkgodsvagnar.
FI903630A0 (fi) Fluoranfoereningar, deras kristallina toluenaddukter, dessa innehaollande upptagningsmaterial och foerfarande foer deras framstaellning.
FI891891A0 (fi) Aminosyraestrar, foerfarande foer deras framstaellning, dessa innehaollande laekemedel och deras anvaendning.
FI905753A0 (fi) Biologiskt nedbrytbara, vattenloesliga polykarboxylsyrakopolymerer, kompositioner innehaollande dylika kopolymerer, och foerfaranden foer anvaendning av saodana polymerer.
FI893498A0 (fi) Anordning foer pressning, avvattning och filtrering.
FI901958A0 (fi) Reninhaemmande dipeptider, foerfarande foer deras framstaellning, dessa innehaollande aemnen och deras anvaendning.
FI904656A0 (fi) Fluoranfoereningar, foerfarande foer deras framstaellning och naemnda foerening innehaollande upptagningsmaterial.
FI895997A (fi) Vaeggkonstruktion, saett och anordning foer bearbetning av vaeggstockar.
FI920474A0 (fi) Elektrofotografiskt framstaelld tryckplatta, med hydrofila tonade omraoden och oleofiliska otonade omraoden.
FI896212A (fi) Dubbningsfoerfarande, holkdubb och dubband.
FI893891A0 (fi) Sophaemtningsfoerfarande, griporgan och sopcontainer.
FI893215A0 (fi) Laosanordning foer foenster, doerrar och liknande.

Legal Events

Date Code Title Description
FD Application lapsed

Owner name: BAYER AKTIENGESELLSCHAFT